Correlation between [18F]FDG PET/CT and volume perfusion CT in primary tumours and mediastinal lymph nodes of non-small-cell lung cancer

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 40, Issue 5, 2013, Pages 677-684

  Sauter, Alexander W ^a   Spira, Daniel ^a   Schulze, Maximilian ^a   Pfannenberg, Christina ^a   Hetzel, Jürgen ^a   Reimold, Matthias ^a   Klotz, Ernst ^b   Claussen, Claus D ^a   Horger, Marius S ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b SIEMENS AG   (Germany)

Author keywords

CT perfusion; FDG PET CT; Mediastinal lymph nodes; NSCLC; Staging; Volume perfusion CT

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT;

ADULT; AGED; ARTICLE; BLOOD FLOW; BLOOD VOLUME; CLINICAL ARTICLE; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; COMPUTER PROGRAM; FEMALE; FLOW EXTRACTION PRODUCT; GLUCOSE METABOLISM; HEMODYNAMIC PARAMETERS; HUMAN; INTERMETHOD COMPARISON; LUNG NON SMALL CELL CANCER; LUNG PERFUSION; MALE; MEDIASTINUM LYMPH NODE; MIDDLE AGED; PET-CT SCANNER; PRIMARY TUMOR; TREATMENT PLANNING; TREATMENT RESPONSE; VERY ELDERLY; LUNG TUMOR; LYMPH NODE METASTASIS; MEDIASTINUM; MULTIMODAL IMAGING; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; RADIOGRAPHY; RECEIVER OPERATING CHARACTERISTIC; SCINTIGRAPHY; SCINTISCANNING; CARCINOMA, NON-SMALL-CELL LUNG; DIAGNOSTIC USE; LUNG NEOPLASMS;

AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MEDIASTINUM; MIDDLE AGED; MULTIMODAL IMAGING; PERFUSION IMAGING; POSITRON-EMISSION TOMOGRAPHY; ROC CURVE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84880095753     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-012-2318-2     Document Type: Article

References (27)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29.
2. Raz DJ, Zell JA, Ou SH, Gandara DR, Anton-Culver H, Jablons DM. Natural history of stage I non-small cell lung cancer: implications for early detection. Chest. 2007;132:193-9.
3. Farray D, Mirkovic N, Albain KS. Multimodality therapy for stage III non-small-cell lung cancer. J Clin Oncol. 2005;23:3257-69.
4. Walker CM, Chung JH, Abbott GF, Little BP, El-Sherief AH, Shepard JA, et al. Mediastinal lymph node staging: from noninvasive to surgical. AJR Am J Roentgenol. 2012;199:W54-64.
5. Silvestri GA, Gould MK, Margolis ML, Tanoue LT, McCrory D, Toloza E, et al. Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest. 2007;132:178S-201.
6. Vansteenkiste JF, Stroobants SG, Dupont PJ, De Leyn PR, DeWever WF, Verbeken EK, et al. FDG-PET scan in potentially operable nonsmall cell lung cancer: do anatometabolic PET-CT fusion images improve the localisation of regional lymph node metastases? The Leuven Lung Cancer Group. Eur J Nucl Med. 1998;25:1495-501.
7. Schmid-Bindert G, Henzler T, Chu TQ, Meyer M, Nance Jr. JW, Schoepf UJ, et al. Functional imaging of lung cancer using dual energy CT: how does iodine related attenuation correlate with standardized uptake value of 18FDG-PET-CT? Eur Radiol. 2012;22:93-103.
8. Mandeville HC, Ng QS, Daley FM, Barber PR, Pierce G, Finch J, et al. Operable non-small cell lung cancer: correlation of volumetric helical dynamic contrast-enhanced CT parameters with immunohistochemical markers of tumor hypoxia. Radiology. 2012;264:581-9.
9. de Langen AJ, van den Boogaart V, Lubberink M, Backes WH, Marcus JT, van Tinteren H, et al. Monitoring response to antiangiogenic therapy in non-small cell lung cancer using imaging markers derived from PET and dynamic contrast-enhanced MRI. J Nucl Med. 2011;52:48-55.
10. Schillaci O, Spanu A, Scopinaro F, Monteleone F, Solinas ME, Volpino P, et al. Mediastinal lymph node involvement in non-small cell lung cancer: evaluation with 99mTc-tetrofosmin SPECT and comparison with CT. J Nucl Med. 2003;44:1219-24.
11. Hoekstra CJ, Stroobants SG, Hoekstra OS, Smit EF, Vansteenkiste JF, Lammertsma AA. Measurement of perfusion in stage IIIA-N2 non-small cell lung cancer using H(2)(15)O and positron emission tomography. Clin Cancer Res. 2002;8:2109-15.
12. Graves EE, Maity A, Le QT. The tumor microenvironment in nonsmall- cell lung cancer. Semin Radiat Oncol. 2010;20:156-63.
13. Le QT, Chen E, Salim A, Cao H, Kong CS, Whyte R, et al. An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. Clin Cancer Res. 2006;12:1507-14.
14. Bollineni VR, Wiegman EM, Pruim J, Groen HJ, Langendijk JA. Hypoxia imaging using positron emission tomography in nonsmall cell lung cancer: implications for radiotherapy. Cancer Treat Rev. 2012;38:1027-32.
15. Veronesi G, Landoni C, Pelosi G, Picchio M, Sonzogni A, Leon ME, et al. Fluoro-deoxi-glucose uptake and angiogenesis are independent biological features in lung metastases. Br J Cancer. 2002;86:1391-5.
16. Hirasawa S, Tsushima Y, Takei H, Hirasawa H, Taketomi-Takahashi A, Takano A, et al. Inverse correlation between tumor perfusion and glucose uptake in human head and neck tumors. Acad Radiol. 2007;14:312-8.
17. Ohno Y, Koyama H, Matsumoto K, Onishi Y, Takenaka D, Fujisawa Y, et al. Differentiation of malignant and benign pulmonary nodules with quantitative first-pass 320-detector row perfusion CT versus FDG PET/CT. Radiology. 2011;258:599-609.
18. Rajendran JG, Mankoff DA, O'Sullivan F, Peterson LM, Schwartz DL, Conrad EU, et al. Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F]fluoromisonidazole and [18F] fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res. 2004;10:2245-52.
19. 18F-FDG, 18F-fluorothymidine, and 18F-misonidazole uptake: a pilot study in mouse models of human non-small cell lung cancer. J Nucl Med. 2012;53:1262-8.
20. 18F-FDG PET for mediastinal staging of lung cancer: which SUV threshold makes sense? J Nucl Med. 2007;48:1761-6.
21. Miles KA, Hayball M, Dixon AK. Colour perfusion imaging: a new application of computed tomography. Lancet. 1991;337:643-5.
22. Tacelli N, Remy-Jardin M, Copin MC, Scherpereel A, Mensier E, Jaillard S, et al. Assessment of non-small cell lung cancer perfusion: pathologic-CT correlation in 15 patients. Radiology. 2010;257:863-71.
23. van den Hoff J. Assessment of lung cancer perfusion by using patlak analysis: what do we measure? Radiology. 2007;243:907-8.
24. Thieme SF, Johnson TR, Lee C, McWilliams J, Becker CR, Reiser MF, et al. Dual-energy CT for the assessment of contrast material distribution in the pulmonary parenchyma. AJR Am J Roentgenol. 2009;193:144-9.
25. Kahraman D, Scheffler M, Zander T, Nogova L, Lammertsma AA, Boellaard R, et al. Quantitative analysis of response to treatment with Erlotinib in advanced non-small cell lung cancer using 18FFDG and 3?-deoxy-3?-18F-fluorothymidine PET. J Nucl Med. 2011;52:1871-7.
26. Yabuuchi H, Hatakenaka M, Takayama K, Matsuo Y, Sunami S, Kamitani T, et al. Non-small cell lung cancer: detection of early response to chemotherapy by using contrast-enhanced dynamic and diffusion-weighted MR imaging. Radiology. 2011;261:598-604.
27. Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst. 2001;93:266-76.